Adriana Luk1, John D Groarke1, Akshay S Desai1, Syed Saad Mahmood1, Deepa M Gopal2, Emer Joyce3, Sachin P Shah4, Joann Lindenfeld5, Lynne Stevenson6, Neal K Lakdawala7. 1. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA. 2. Boston University Medical Center, Boston, MA. 3. The Cleveland Clinic, Cleveland, OH. 4. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Lahey Hospital and Medical Center, Burlington, MA. 5. Vanderbilt University Medical Center, Nashville, TN. 6. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Vanderbilt University Medical Center, Nashville, TN. 7. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA. Electronic address: nlakdawala@partners.org.
Abstract
BACKGROUND: Relief of congestion is the primary goal of initial therapy for acute decompensated heart failure (ADHF). Early measurement of urine sodium concentration (UNa) may be useful to identify patients with diminished response to diuretics. The aim of this study was to determine if the first spot UNa after diuretic initiation could select patients likely to require more intensive therapy during hospitalization. METHODS: At the time of admission, 103 patients with ADHF were identified prospectively, and UNa was measured after the first dose of intravenous diuretic. Clinical outcomes were compared for patients with UNa >60 mmol/L and UNa of ≤60 mmol/L, with the primary outcome of a composite of death at 90 days, mechanical circulatory support during admission, and requirement of inotropic support at discharge. RESULTS: Patients with UNa ≤60 had lower admission blood pressure, had less chronic neurohormonal antagonist prior to admission, and were more than twice as likely to experience the primary end point (hazard ratio 2.40, 95% CI 1.02-5.66, P = .045), which was marginally significant after adjusting for renal function and baseline home loop diuretic. Worsening renal function was significantly more common in patients with UNa <60 (23.6% vs 6.5%, P = .05). Although the initial assessment of congestion was similar at admission, patients with low early UNa had a longer length of stay (11 vs 6 days, P < .006) than patients with UNa >60. CONCLUSIONS: Assessment of spot UNa after initial intravenous loop diuretic administration may facilitate identification and triage of a population of HF patients at increased risk for adverse events and prolonged hospitalization.
BACKGROUND: Relief of congestion is the primary goal of initial therapy for acute decompensated heart failure (ADHF). Early measurement of urine sodium concentration (UNa) may be useful to identify patients with diminished response to diuretics. The aim of this study was to determine if the first spot UNa after diuretic initiation could select patients likely to require more intensive therapy during hospitalization. METHODS: At the time of admission, 103 patients with ADHF were identified prospectively, and UNa was measured after the first dose of intravenous diuretic. Clinical outcomes were compared for patients with UNa >60 mmol/L and UNa of ≤60 mmol/L, with the primary outcome of a composite of death at 90 days, mechanical circulatory support during admission, and requirement of inotropic support at discharge. RESULTS:Patients with UNa ≤60 had lower admission blood pressure, had less chronic neurohormonal antagonist prior to admission, and were more than twice as likely to experience the primary end point (hazard ratio 2.40, 95% CI 1.02-5.66, P = .045), which was marginally significant after adjusting for renal function and baseline home loop diuretic. Worsening renal function was significantly more common in patients with UNa <60 (23.6% vs 6.5%, P = .05). Although the initial assessment of congestion was similar at admission, patients with low early UNa had a longer length of stay (11 vs 6 days, P < .006) than patients with UNa >60. CONCLUSIONS: Assessment of spot UNa after initial intravenous loop diuretic administration may facilitate identification and triage of a population of HF patients at increased risk for adverse events and prolonged hospitalization.
Authors: Veena S Rao; Juan B Ivey-Miranda; Zachary L Cox; Ralph Riello; Matthew Griffin; James Fleming; Richard Soucier; Prasama Sangkachand; Margaret O'Brien; Francine LoRusso; Julie D'Ambrosi; Keith Churchwell; Devin Mahoney; Lavanya Bellumkonda; Jennifer L Asher; Christopher Maulion; Jeffrey M Turner; F Perry Wilson; Sean P Collins; Jeffrey M Testani Journal: J Am Coll Cardiol Date: 2021-02-16 Impact factor: 24.094
Authors: Saif Ali; Sharon Jung; Shuktika Nandkeolyar; Liset Stoletniy; Antoine Sakr; Frederik H Verbrugge; Anthony Hilliard; Dmitry Abramov Journal: Am J Cardiovasc Drugs Date: 2021-03-12 Impact factor: 3.571
Authors: Jonathan W Cunningham; Jie-Lena Sun; Finnian R Mc Causland; Samantha Ly; Kevin J Anstrom; Joann Lindenfeld; Michael M Givertz; Lynne W Stevenson; Neal K Lakdawala Journal: Clin Cardiol Date: 2019-11-12 Impact factor: 2.882
Authors: Belén García-Magallón; Marta Cobo-Marcos; Aitor Dávila Martiarena; Esther Montero Hernández; Maria Luisa Martín Jiménez; Aránzazu Martín García; Daniel De Castro Campos; Paula Vela Martín; Fernando Hernández Terciado; Ramón Garrido González; Andrea Matutano Muñoz; Daniel Escribano García; Fernando Domínguez; Ana Sainz Herrero; Camino Gómez Peñalba; Pablo Garcia-Pavia; Javier Segovia Journal: Front Physiol Date: 2022-05-02 Impact factor: 4.566
Authors: Kerry A Loughran; Éva Larouche-Lebel; Terry Huh; Jeffrey M Testani; Veena S Rao; Mark A Oyama Journal: J Vet Intern Med Date: 2020-10-30 Impact factor: 3.333